This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kugiyama, K. Articles by Yasue, H. Search for Related Content PubMed PubMed Citation Articles by Kugiyama, K. Articles by Yasue, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cholesterol

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:1080-1087.)
© 1996 American Heart Association, Inc.

Articles

Suppression of Atherosclerotic Changes in Cholesterol-Fed Rabbits Treated With an Oral Inhibitor of Neutral Endopeptidase 24.11 (EC 3.4.24.11)

Kiyotaka Kugiyama; Seigo Sugiyama; Toshiyuki Matsumura; Yasutaka Ohta; Hideki Doi; Hirofumi Yasue

the Division of Cardiology, Kumamoto University School of Medicine, Kumamoto City, Japan.

Correspondence to Kiyotaka Kugiyama, MD, Division of Cardiology, Kumamoto University School of Medicine, Honjo 1-1-1, Kumamoto City, Japan 860.

Neutral endopeptidase 24.11 (NEP), widely distributed in the body, hydrolyzes and inactivates a number of endogenous vasoactive peptides, some of which could alter various functions of cells present in the arterial wall. Recently NEP has been found to exist in the vascular endothelium. The aim of this study was to assess the influence of chronic NEP inhibition by daily administration of UK79300 (candoxatril), an orally active NEP inhibitor (NEPI), on the development of atherosclerotic changes in high-cholesterol-fed rabbits. Male New Zealand White rabbits were fed for 8 weeks as follows: normal rabbit diet (Normal, n=15), 1.5% cholesterol diet (Cholesterol, n=15), or 1.5% cholesterol diet containing NEPI (20 mg·kg^-1·d^-1) (Cholesterol+NEPI, n=15). At the end of the dietary period, NEPI treatment was found to suppress the surface area of the aorta covered by plaques (% surface area: Cholesterol, 59±6 versus Cholesterol+NEPI, 36±7, P<.01) and decreased contents of cholesterol and cholesterol esters in the aortas. NEPI also reduced plasma total cholesterol by 27% of Cholesterol rabbits (1781±130 mg/dL). The endothelial function, estimated by the endothelium-dependent relaxation of the isolated aortas in response to acetylcholine, was preserved in Cholesterol+NEPI rabbits compared with that in Cholesterol rabbits. NEP enzymatic activities in plasma and the particulate fraction of the homogenates from the aortas in Cholesterol rabbits were both increased, 3.1- and 3.9-fold, respectively, above those in Normal rabbits, but the activities in Cholesterol+NEPI rabbits were significantly lower than those in Cholesterol rabbits. UK73967, an active form of UK79300, or phosphoramidon partly reversed the atherosclerotic impairment of relaxation of the isolated thoracic aortic rings from Cholesterol rabbits in response to exogenous additions of C-type natriuretic peptide (CNP) and substance P, which are NEP substrates known to exist endogenously in the vascular endothelium. The results suggest that the increased NEP activity plays a significant role in atherogenesis, and NEPIs might be therapeutically useful in the prevention of atherosclerosis. Reduction of plasma cholesterol and suppression of degradations in the arteries of endogenously released CNP, substance P, or possibly other kinins known to have anti-atherosclerotic actions may at least partially contribute to the inhibitory effects of NEPIs on atherosclerotic changes.

Key Words: neutral endopeptidase 24.11 • atherosclerosis • endothelium-dependent relaxation • endothelium • C-type natriuretic peptide

This article has been cited by other articles:

				M. N. Barber, M. Kanagasundaram, C. R. Anderson, L. M. Burrell, and R. L. Woods Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia Cardiovasc Res, July 1, 2006; 71(1): 179 - 188. [Abstract] [Full Text] [PDF]

				N. Weckler, D. Leitzbach, L. Kalinowski, T. Malinski, A. E Busch, and W. Linz Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 191 - 196. [Abstract] [PDF]

				M. C. Petrie, C. Hillier, F. Johnston, and J. J.V. McMurray Effect of Neutral Endopeptidase Inhibition on the Actions of Adrenomedullin and Endothelin-1 in Resistance Arteries From Patients With Chronic Heart Failure Hypertension, September 1, 2001; 38(3): 412 - 416. [Abstract] [Full Text] [PDF]

				J. A. Grantham, J. A. Schirger, P. W. Wennberg, S. Sandberg, D. M. Heublein, T. Subkowski, and J. C. Burnett Jr Modulation of Functionally Active Endothelin-Converting Enzyme by Chronic Neutral Endopeptidase Inhibition in Experimental Atherosclerosis Circulation, April 25, 2000; 101(16): 1976 - 1981. [Abstract] [Full Text] [PDF]

				J. A. Schirger, J. A. Grantham, I. J. Kullo, M. Jougasaki, P. W. Wennberg, H. H. Chen, O. Lisy, V. Miller, R. D. Simari, and J. C. Burnett Jr. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition J. Am. Coll. Cardiol., March 1, 2000; 35(3): 796 - 801. [Abstract] [Full Text] [PDF]

				T. Matsumura, K. Kugiyama, S. Sugiyama, Y. Ota, H. Doi, N. Ogata, H. Oka, and H. Yasue Suppression of Atherosclerotic Development in Watanabe Heritable Hyperlipidemic Rabbits Treated With an Oral Antiallergic Drug, Tranilast Circulation, February 23, 1999; 99(7): 919 - 924. [Abstract] [Full Text] [PDF]